Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, D Cortinovis, F Cappuzzo… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
C Gridelli, F De Marinis, M Di Maio… - Lung Cancer …, 2011 - europepmc.org
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for …
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - LUNG CANCER, 2011 - boa.unimib.it
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for …
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - infona.pl
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
[引用][C] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for …
C GRIDELLI, F DE MARINIS, M DI MAIO… - Lung …, 2011 - pascal-francis.inist.fr
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with
activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and …
activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for …
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio… - Lung …, 2011 - lungcancerjournal.info
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for …
C Gridelli, F De Marinis, M Di Maio… - Lung cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment …
[引用][C] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for …
C Gridelli, F De Marinis, M DI MAIO, D Cortinovis… - LUNG CANCER, 2011 - iris.unito.it
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with
activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and …
activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and …
[引用][C] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for …
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - cir.nii.ac.jp
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with
activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and …
activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and …